PURA - Puration Maintains $4 Million and $8 Million Revenue Targets for 2019 and 2020
November 26 2019 - 9:13AM
InvestorsHub NewsWire
PURA – Puration Maintains $4
Million and $8 Million Revenue Targets for 2019 and 2020
Dallas, TX -- November 26, 2019 --
InvestorsHub NewsWire -- Puration, Inc. (USOTC:
PURA) today published a management update with a review of the
most recent financial report filed for the period ended September
30, 2019 and including an update on the company’s $4 million 2019
revenue target and plans for reaching $8 million in 2020 in light
of the most recent financial
report.
PURA reported $1,895,000 in revenue
year-to-date through the period ending September 30, 2019.
The year-to-date revenue reflects over one hundred percent (100%)
growth. The company also realized a twelve (12%) percent
increase in net profit to $232,500 for the same
period.
Were sales to remain relatively steady
from Q3 to Q4, the 2019 annual income would come in at
approximately $2.7 million. To reach the $4 million 2019
revenue target will require an additional approximate $1.3 million
in sales. With major distribution agreements recently signed
in Europe and Latin America that include initial shipments
currently in progress, management indicates that the $4 million
target remains within reach. The potential of reaching the $4
million sales target is bolstered by the company’s recent
introduction of TranquiliTea
CBD adding
to its existing EVERx CBD
Sports Water. Being on pace to exceed 100%
revenue growth is an achievement in and of itself aside from the $4
million revenue target. Management believes the 2020 $8
million revenue target remains an achievable goal and one that can
be potentially substantially surpassed. Management is pleased
with the company’s growth to date and continuing growth
potential.
For more information on Puration,
visit http://www.purationinc.com
Disclaimer/Safe
Harbor:
This news release contains forward-looking
statements within the meaning of the Securities Litigation Reform
Act. The statements reflect the Company's current views with
respect to future events that involve risks and uncertainties.
Among others, these risks include the expectation that any of the
companies mentioned herein will achieve significant sales, the
failure to meet schedule or performance requirements of the
companies' contracts, the companies' liquidity position, the
companies' ability to obtain new contracts, the emergence of
competitors with greater financial resources and the impact of
competitive pricing. In the light of these uncertainties, the
forward-looking events referred to in this release might not occur.
These statements have not been evaluated by the Food and Drug
Administration. These products are not intended to diagnose, treat,
cure, or prevent any disease.
Contact:
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800)
861-1350
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Sep 2023 to Sep 2024